Staden U, Rolinck-Werninghaus C, Brewe F, Wahn U, Niggemann B, Beyer K
Department of Pediatric Pneumology and Immunology, University Children's Hospital Charité, Berlin, Germany.
Allergy. 2007 Nov;62(11):1261-9. doi: 10.1111/j.1398-9995.2007.01501.x.
Specific oral tolerance induction (SOTI) seems to be a promising treatment of food allergy. Specific oral tolerance induction and elimination diet were compared with respect to efficacy rate and patterns of clinical reaction.
Children with challenge proven immunoglobulin E (IgE)-mediated cow's milk (CM) allergy or hen's egg (HE) allergy were randomly assigned to SOTI or elimination diet as a control group. Specific oral tolerance induction treatment was performed at home on a daily basis according to a study protocol with fresh CM or lyophilized HE protein. Re-evaluation of clinically relevant food allergy was performed by food challenge after a median of 21 months. Children in the SOTI group received a secondary elimination diet for 2 months prior to follow-up challenge to evaluate persistence of induced oral tolerance.
At follow-up challenge, nine of 25 children (36%) showed permanent tolerance in the SOTI group, three of 25 (12%) were tolerant with regular intake and four of 25 (16%) were partial responders. In the control group, seven of 20 children (35%) were tolerant. Allergen-specific immunoglobulin E decreased significantly both in children who developed natural tolerance during the elimination diet (P < 0.05) and in those with SOTI (P < 0.001).
Specific oral tolerance induction seems a valid treatment option for patients with persistent food allergy. Indications may be given if avoidance cannot be guaranteed or for those who are eager to eat the food in question. Advantages of SOTI are the increased threshold dose for allergic reactions and the substantially reduced risk of severe allergic reactions after inadvertent ingestion of the allergen. However, careful monitoring during SOTI is mandatory.
特异性口服耐受诱导(SOTI)似乎是一种很有前景的食物过敏治疗方法。对特异性口服耐受诱导和排除饮食的有效率及临床反应模式进行了比较。
经激发试验证实为免疫球蛋白E(IgE)介导的牛奶(CM)过敏或鸡蛋(HE)过敏的儿童被随机分为SOTI组或作为对照组的排除饮食组。根据研究方案,在家中每天使用新鲜CM或冻干HE蛋白进行特异性口服耐受诱导治疗。在中位21个月后通过食物激发试验对临床相关食物过敏进行重新评估。SOTI组的儿童在随访激发试验前接受2个月 的二次排除饮食,以评估诱导的口服耐受的持续性。
在随访激发试验中,SOTI组25名儿童中有9名(36%)表现出永久耐受,25名中有3名(12%)在规律摄入时耐受,25名中有4名(16%)为部分反应者。对照组中,20名儿童中有7名(35%)耐受。在排除饮食期间产生自然耐受的儿童(P<0.05)和接受SOTI的儿童(P<0.001)中,过敏原特异性免疫球蛋白E均显著下降。
特异性口服耐受诱导似乎是持续性食物过敏患者的一种有效治疗选择。如果无法保证避免接触过敏原或对于渴望食用相关食物的患者,可以考虑采用该方法。SOTI的优点是过敏反应的阈值剂量增加,无意中摄入过敏原后严重过敏反应的风险大幅降低。然而,在SOTI期间必须进行仔细监测。